ArticleMolecular biology reports2012
Topical application of a phospholipid mixture purified from pig lungs ameliorates 2,4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice.
Article in Molecular biology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Hair growth promoting potential of phospholipids purified from porcine lung tissues.Biomolecules & therapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work was designed to assess the pharmacological effectiveness as a novel anti-atopic dermatitis remedy of a phopholipid mixture purified from pig lung tissues, named KT&G101, using the BALB/c mouse model of allergic contact dermatitis. Allergic contact dermatitis was induced by applying 2,4-dinitrofluorobenzene (DNFB) epicutaneously onto the dorsal skins of mice, and KT&G101 was topically applied onto the skin areas with the lesions. The topical application of KT&G101 (0.05 ml of 10 mg/ml and 20 mg/ml KT&G101, twice a day for 15 days) decreased the total IgE level elevated in the sera of mice undergoing allergic contact dermatitis. KT&G101 was also able to decrease the 2,4-dinitrophenyl (DNP)-specific IgE level elevated in the sera of the model mice. It reduced the incidences of scratching behaviors in the mice undergoing DNFB-induced allergic contact dermatitis. It attenuated some histopathological changes, such as pustule, epidermal hyperplasia, dermatitis and fibroplasia, while it could enhance the recovery of epidermis, in the damaged skin tissues within a relatively short period after the topical application of KT&G101. KT&G101 lessened the expression of cytokines mRNAs, such as Th1-specific IL-2, TNF-β and IFN-γ, and Th2-specific IL-4, in the mouse skin tissues showing the lesions. In brief, it is concluded that KT&G101 alleviates the symptoms involved in induced allergic contact dermatitis in BALB/c mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.